Standard Chem & Pharm Co Ltd
TWSE:1720
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
60.9
78.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Standard Chem & Pharm Co Ltd
Standard Chem & Pharm Co Ltd
Total Equity
Standard Chem & Pharm Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Total Equity
NT$5.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Total Equity
NT$7.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Total Equity
NT$7.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Total Equity
NT$10.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Total Equity
NT$5.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Total Equity
NT$17.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
|
Standard Chem & Pharm Co Ltd
Glance View
Standard Chemical & Pharmaceutical Co., Ltd. engages in the manufacture and sale of Chinese and western medicine, medicine raw materials, and health food. The company is headquartered in Tainan, Tainan. The Company’s products cover drugs for circulation systems, digest systems, respiratory systems, nervous systems and other diseases. Through its subsidiaries, the Company is also engaged in the sales of medical equipment, animal medicine, milk powder, cosmetics and others. The firm distributes its products both in domestic markets and overseas markets.
See Also
What is Standard Chem & Pharm Co Ltd's Total Equity?
Total Equity
5.8B
TWD
Based on the financial report for Jun 30, 2024, Standard Chem & Pharm Co Ltd's Total Equity amounts to 5.8B TWD.
What is Standard Chem & Pharm Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
7%
Over the last year, the Total Equity growth was 21%. The average annual Total Equity growth rates for Standard Chem & Pharm Co Ltd have been 13% over the past three years , 10% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet
